Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis.
Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli AM, Nepote A, Maccioni A, Scartozzi M, Solinas C, Novello S. Bertaglia V, et al. Among authors: novello s. Semin Oncol. 2024 Dec 31:S0093-7754(24)00064-2. doi: 10.1053/j.seminoncol.2024.11.001. Online ahead of print. Semin Oncol. 2024. PMID: 39743384 Free article. Review.
Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.
Salaroglio IC, Aviles P, Kopecka J, Merlini A, Napoli F, Righi L, Novello S, Sullivan H, Cuevas C, Scagliotti GV, Riganti C. Salaroglio IC, et al. Among authors: novello s. J Exp Clin Cancer Res. 2024 Dec 21;43(1):327. doi: 10.1186/s13046-024-03253-y. J Exp Clin Cancer Res. 2024. PMID: 39709435 Free PMC article.
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).
Passiglia F, Listì A, Bironzo P, Merlini A, Benso F, Napoli F, Barbu FA, Zambelli V, Tabbò F, Reale ML, Sini C, Roca E, Taveggia PA, Simionato F, Buffoni L, Mazilu L, Barbieri V, Pignataro D, Araujo A, Paz-Ares L, Felip E, Secen N, Comanescu A, Ramizi KM, Bettini AC, Scotti V, Linardou H, Mohorcic K, Meoni G, Giannarelli D, Volante M, Malapelle U, Vallone S, Scagliotti G, Righi L, Novello S. Passiglia F, et al. Among authors: novello s. J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529-2. doi: 10.1016/j.jtho.2024.12.010. Online ahead of print. J Thorac Oncol. 2024. PMID: 39694416 Free article.
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: novello s. J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032. Online ahead of print. J Thorac Oncol. 2024. PMID: 39622410 Free article.
Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review.
Nepote A, Poletto S, Bertaglia V, Carnio S, Piumatti C, Lanzetta C, Cantale O, Saba G, Bironzo P, Novello S, Tralongo AC. Nepote A, et al. Among authors: novello s. Crit Rev Oncol Hematol. 2025 Jan;205:104540. doi: 10.1016/j.critrevonc.2024.104540. Epub 2024 Oct 30. Crit Rev Oncol Hematol. 2025. PMID: 39486561 Review.
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes.
Bertolaccini L, Tralongo AC, Del Re M, Facchinetti F, Ferrara R, Franchina T, Graziano P, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Cinquini M, Passiglia F, Novello S. Bertolaccini L, et al. Among authors: novello s. Lung Cancer. 2024 Nov;197:107990. doi: 10.1016/j.lungcan.2024.107990. Epub 2024 Oct 21. Lung Cancer. 2024. PMID: 39461280
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates.
Dall'Olio FG, Zrafi W, Roelants V, Ambrosini V, Fourquet A, Mitea C, Passiglia F, Bauckneht M, Bonardel G, Conci N, Benitez JC, Arena V, Namour C, Naigeon M, Monnet I, Beshiri K, Hoton D, Dursun S, Danlos FX, Argalia G, Aldea M, Rovera G, Derosa L, Iebba V, Gietema HA, Gounant V, Lacroix V, Remon J, Gautheret D, Chaput N, Job B, Kannouche PL, Velasco-Nuño M, Zitvogel L, Cella E, Chícharo de Freitas JR, Vasseur D, Bettaieb MA, Tagliamento M, Hendriks L, Italiano A, Planchard D, Marabelle A, Barlesi F, Novello S, De Andreis D, Aboubakar Nan F, Ardizzoni A, Zalcman G, Garcia C, Besse B. Dall'Olio FG, et al. Among authors: novello s. Clin Cancer Res. 2024 Oct 22. doi: 10.1158/1078-0432.CCR-24-1993. Online ahead of print. Clin Cancer Res. 2024. PMID: 39437011
From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment.
Picca F, Giannotta C, Tao J, Giordanengo L, Munir HMW, Botta V, Merlini A, Mogavero A, Garbo E, Poletto S, Bironzo P, Doronzo G, Novello S, Taulli R, Bersani F. Picca F, et al. Among authors: novello s. Int J Mol Sci. 2024 Oct 9;25(19):10823. doi: 10.3390/ijms251910823. Int J Mol Sci. 2024. PMID: 39409152 Free PMC article. Review.
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Waterhouse DM, et al. Among authors: novello s. Lung Cancer. 2024 Oct;196:107921. doi: 10.1016/j.lungcan.2024.107921. Epub 2024 Aug 6. Lung Cancer. 2024. PMID: 39303400 Free article. Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Among authors: novello s. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
522 results